SYK is currently trading at $374.22, with a strong resistance level at $380. The stock is approaching this resistance, and the Fibonacci retracement levels suggest a potential upside to $383.09. The MACD and RSI indicators show a bullish signal, indicating potential for an upward movement.
The $380 call option has a bid of $12.30, offering a 1% premium. This suggests that there's a possibility of the stock reaching $380, which aligns with the analyst target. The probability of the call expiring worthless is 48%, but there's still a chance the stock could move higher.
SYK has been performing well, with positive mentions in the ETF analysis and factor-based analysis. The Partha Mohanram model gives SYK a 66% score, indicating sustained growth potential. However, there was an insider sale, which might indicate some caution, but it's not a major red flag.
Based on the technical indicators, analyst targets, and options data, I predict SYK will reach approximately $380 next week. It's a good time to buy, as the stock has the potential to break through the resistance level and move higher.
The price of SYK is predicted to go up 19.17%, based on the high correlation periods with SQM. The similarity of these two price pattern on the periods is 96.49%.
SYK
SQM
Year
SYK Price Forecast($)
Potential Return(%)
2025
363.010
0.410
2026
450.000
16.520
2027
440.250
14.000
2028
520.000
34.650
2029
520.000
34.650
2030
600.000
55.360
Stryker made the most of its three-year head start in placing its Mako robots in hospitals, leaving Zimmer Biomet and Johnson & Johnson to play catch-up.
As hospitals and healthcare systems aim to consolidate suppliers, Stryker should benefit because those customers are more likely to stick with the most widely used brands to accommodate more of their surgeons.
Considering how resistant orthopedic surgeons are to hospital efforts to restrict brand choice and the slow transition to hospital employment, we think surgeon influence will wane slowly.
Citigroup
2025-02-26
Price Target
$450
Upside
+14.87%
Barclays
2025-02-10
Price Target
$418 → $443
Upside
+12.84%
Goldman Sachs
2025-01-30
Price Target
$384 → $427
Upside
+9.37%